(ROIV) Roivant Sciences - Overview
Stock: Antibody, Small-Molecule, Inhaled, LNP, Ligand-Conjugate
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 81.7% |
| Relative Tail Risk | -11.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.29 |
| Alpha | 121.67 |
| Character TTM | |
|---|---|
| Beta | 0.831 |
| Beta Downside | 0.540 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.47% |
| CAGR/Max DD | 1.33 |
Description: ROIV Roivant Sciences January 08, 2026
Roivant Sciences Ltd. (NASDAQ: ROIV) is a London-based, clinical-stage biopharma that builds and runs a portfolio of specialty-focused subsidiaries (“Vants”) to discover, develop, and commercialize novel medicines and delivery technologies.
Its pipeline is anchored by three antibody programs-IMVT-1402 (targeting the neonatal Fc receptor for Graves’ disease and several autoimmune disorders), batoclimab (for thyroid eye disease), and brepocitinib (a TYK2/JAK1 inhibitor for dermatomyositis, non-infectious uveitis, and related conditions)-plus a lead small-molecule inhaled sGC activator, mosliciguat, aimed at pulmonary hypertension secondary to interstitial lung disease and other cardiopulmonary indications.
Beyond drug candidates, Roivant leverages two proprietary delivery platforms: a lipid-nanoparticle (LNP) system for nucleic-acid therapeutics and a ligand-conjugate platform designed to improve tissue targeting and dosing efficiency.
Key quantitative signals (Q2 2024) show the company holding roughly $560 million in cash and equivalents, translating to an estimated 18-month runway at its current burn rate; R&D spend has risen ~22 % YoY, reflecting accelerated late-stage trial activity. The broader biotech sector continues to benefit from robust venture capital inflows (global biotech VC funding hit $46 billion in 2023) and an expanding market for immunology therapeutics, which underpins demand for Roivant’s pipeline.
For a deeper dive into Roivant’s valuation metrics and peer comparisons, the ValueRay platform offers a concise, data-rich overview.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -374.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA -2.91 > 1.0 |
| NWC/Revenue: 21.5k% < 20% (prev 14.2k%; Δ 7377 % < -1%) |
| CFO/TA -0.15 > 3% & CFO -769.9m > Net Income -374.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 33.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (680.9m) vs 12m ago -7.41% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.36% > 50% (prev 0.60%; Δ -0.24% > 0%) |
| Interest Coverage Ratio: -7.30 > 6 (EBITDA TTM -996.9m / Interest Expense TTM -137.4m) |
Altman Z'' 2.53
| A: 0.86 (Total Current Assets 4.51b - Total Current Liabilities 133.9m) / Total Assets 5.06b |
| B: -0.08 (Retained Earnings -429.1m / Total Assets 5.06b) |
| C: -0.18 (EBIT TTM -1.00b / Avg Total Assets 5.63b) |
| D: -1.59 (Book Value of Equity -409.5m / Total Liabilities 257.1m) |
| Altman-Z'' Score: 2.53 = A |
What is the price of ROIV shares?
Over the past week, the price has changed by +19.43%, over one month by +19.48%, over three months by +25.52% and over the past year by +137.53%.
Is ROIV a buy, sell or hold?
- StrongBuy: 6
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ROIV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 27 | 4.6% |
| Analysts Target Price | 27 | 4.6% |
| ValueRay Target Price | 35.6 | 37.8% |
ROIV Fundamental Data Overview February 07, 2026
P/B = 3.4501
Revenue TTM = 20.3m USD
EBIT TTM = -1.00b USD
EBITDA TTM = -996.9m USD
Long Term Debt = 98.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 9.00m USD (from shortTermDebt, last quarter)
Debt = 98.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.14b USD (from netDebt column, last quarter)
Enterprise Value = 10.42b USD (14.70b + Debt 98.8m - CCE 4.39b)
Interest Coverage Ratio = -7.30 (Ebit TTM -1.00b / Interest Expense TTM -137.4m)
EV/FCF = -13.28x (Enterprise Value 10.42b / FCF TTM -784.4m)
FCF Yield = -7.53% (FCF TTM -784.4m / Enterprise Value 10.42b)
FCF Margin = -3858 % (FCF TTM -784.4m / Revenue TTM 20.3m)
Net Margin = -1840 % (Net Income TTM -374.0m / Revenue TTM 20.3m)
Gross Margin = unknown ((Revenue TTM 20.3m - Cost of Revenue TTM 729.0k) / Revenue TTM)
Tobins Q-Ratio = 2.06 (Enterprise Value 10.42b / Total Assets 5.06b)
Interest Expense / Debt = 13.56% (Interest Expense 13.4m / Debt 98.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -792.6m (EBIT -1.00b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 33.70 (Total Current Assets 4.51b / Total Current Liabilities 133.9m)
Debt / Equity = 0.02 (Debt 98.8m / totalStockholderEquity, last quarter 4.36b)
Debt / EBITDA = 1.14 (negative EBITDA) (Net Debt -1.14b / EBITDA -996.9m)
Debt / FCF = 1.45 (negative FCF - burning cash) (Net Debt -1.14b / FCF TTM -784.4m)
Total Stockholder Equity = 4.65b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.64% (Net Income -374.0m / Total Assets 5.06b)
RoE = -8.05% (Net Income TTM -374.0m / Total Stockholder Equity 4.65b)
RoCE = -21.14% (EBIT -1.00b / Capital Employed (Equity 4.65b + L.T.Debt 98.8m))
RoIC = -17.06% (negative operating profit) (NOPAT -792.6m / Invested Capital 4.65b)
WACC = 8.99% (E(14.70b)/V(14.80b) * Re(8.98%) + D(98.8m)/V(14.80b) * Rd(13.56%) * (1-Tc(0.21)))
Discount Rate = 8.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -10.20%
Fair Price DCF = unknown (Cash Flow -784.4m)
EPS Correlation: 58.60 | EPS CAGR: 21.70% | SUE: 2.18 | # QB: 2
Revenue Correlation: -61.69 | Revenue CAGR: -51.85% | SUE: -0.12 | # QB: 0
EPS next Year (2027-03-31): EPS=-1.13 | Chg30d=+0.060 | Revisions Net=+1 | Growth EPS=-3.6% | Growth Revenue=+641.1%